Functional Electrical Stimulation for MDD
4 juni 2026 bijgewerkt door: Unity Health Toronto
Functional Electrical Stimulation for Major Depressive Disorder: A Pilot Randomized Control Trial
This study aims to determine whether Functional Electrical Stimulation (FES) of the facial muscles is a safe and effective treatment for major depressive disorder (MDD).
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
A potential new treatment for Major Depressive Disorder (MDD) involves using a Functional Electrical Stimulation (FES) device to stimulate specific facial muscles. By targeting muscles related to smile patterns, FES has shown promise in improving emotional control and boosting mood. This project aims to address a critical need for innovative treatments for MDD, especially since 30% of MDD patients do not respond to traditional treatments.
This is a single-site clinical trial that is double-blind, randomized, and sham-controlled, involving 20 sessions of FES over four weeks. The trial will assess the effectiveness, safety, and tolerability of FES for individuals with mild-to-moderate major depressive episode (MDE) and a primary diagnosis of MDD.
Participants in the study will have a total of 26 visits: one screening and one baseline visit (both conducted by phone), followed by 20 on-site intervention visits over four weeks (one sessions per day). After the treatment, there will also be four follow-up visits over the phone to check how long the effects of the FES treatment last.
Studietype
Ingrijpend
Inschrijving (Geschat)
60
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Venkat Bhat
- Telefoonnummer: 76404 416-360-4000
- E-mail: Venkat.Bhat@unityhealth.to
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
Patients will be included if they:
- Meet the DSM-5 criteria for unipolar MDD with a current MDE without psychotic features, with ≤ 2 failed treatment trials (non-treatment-resistant depression), validated by MINI done by a trained research assistant.
- Have no change in the medication regimen or other forms of treatments (e.g., psychotherapy) for at least 4 weeks (28 days) prior to beginning the study, and have no plan to change them during the 20-session treatment period (14 days), and the 4-week post-treatment observation period. This will be established through self-report, in combination with the ATHF filled out by the participant.
- Have an MDD diagnosis as confirmed by the MADRS score of ≥7.
- Age group between 18 and 70 years of age
Exclusion Criteria:
Patients will be excluded if they:
- History of epilepsy or seizures.
- Damage or dysfunction of facial nerves.
- Metallic orthopedic implants in the mouth (e.g., plates or screws).
- Current fibromyalgia or currently receiving or have received rTMS within the last 28 days before the screening.
- History of treatment-resistant depression (TRD) with history of ECT, Magnetic Seizure Therapy, Intravenous Ketamine use in the past or failure of >2 antidepressant treatments of adequate duration and dose during the current episode.
- Past or current symptoms of mania, hypomania, mixed episodes, psychotic disorders, obsessive-compulsive disorder, post-traumatic stress disorder, active substance abuse or dependence (excluding nicotine and caffeine), neurodegenerative disease, or dementia. This will be confirmed on the MINI (77) administered by a trained research assistant.
- Current suicidal intent or plan as demonstrated by a score of ≥4 on MADRS item 10.
- Unable to understand instructions in English.
- Unable to produce "Duchenne marker" expression with FES, secondary to any type of neurological condition or previous botulinum toxin treatments of facial muscles.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Active FES
Functional Electrical Stimulation (FES) will be administered to four facial muscles involved in smiling, with two muscles targeted on each side of the face.
Electrodes will be placed over the target muscles, and stimulation will be delivered using standard muscle-activation settings.
|
Once per day for the duration of 4 weeks.
Total of 20 sessions (each session lasts 60 mins)
|
|
Sham-vergelijker: Sham FES
Sham Functional Electrical Stimulation (FES) will be administered using the same electrode placement and session schedule as the active FES arm.
Stimulation will be delivered at a low sensory intensity range of 1-8 mA, sufficient for participants to feel the stimulation, while other parameters will remain the same as in the active arm.
Sham stimulation will be delivered in a non-Duchenne smile pattern.
|
Once per day for the duration of 4 weeks.
Total of 20 sessions (each session lasts 60 mins)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Efficacy of FES: Change in Depression Severity
Tijdsspanne: 4 weeks of Intervention, 4 weeks of follow-up
|
Change in depression severity measured using the 17-item Hamilton Depression Rating Scale (HAM-D-17).
Scores range from 0 to 52, with higher scores indicating more severe depressive symptoms.
|
4 weeks of Intervention, 4 weeks of follow-up
|
|
Tolerability of FES
Tijdsspanne: 4 weeks of Intervention, 4 weeks of follow-up
|
The overall dropout and protocol compliance rates will be assessed.
|
4 weeks of Intervention, 4 weeks of follow-up
|
|
FES safety
Tijdsspanne: 4 weeks of Intervention, 4 weeks of follow-up
|
The number and nature of adverse events will be assessed
|
4 weeks of Intervention, 4 weeks of follow-up
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Anxiety Symptoms
Tijdsspanne: 4 weeks of Intervention, 4 weeks of follow-up
|
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7.
Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.
|
4 weeks of Intervention, 4 weeks of follow-up
|
|
Change in Well-Being
Tijdsspanne: 4 weeks of Intervention, 4 weeks of follow-up
|
Well-being will be assessed using the World Health Organization-Five Well-Being Index.
Raw total scores range from 0 to 25, with higher scores indicating better well-being.
|
4 weeks of Intervention, 4 weeks of follow-up
|
|
Change in Sleep Quality
Tijdsspanne: 4 weeks of Intervention, 4 weeks of follow-up
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index.
Global scores range from 0 to 21, with higher scores indicating poorer sleep quality.
|
4 weeks of Intervention, 4 weeks of follow-up
|
|
Response and Remission Rate
Tijdsspanne: 4 weeks of Intervention, 4 weeks of follow-up
|
Response and Remission will be assessed using the 17-item Hamilton Depression Rating Scale.
Total scores on the 17-item Hamilton Depression Rating Scale range from 0 to 52, with higher scores indicating greater depression symptom severity.
|
4 weeks of Intervention, 4 weeks of follow-up
|
|
Changes in Facial Expressivity
Tijdsspanne: 4 weeks of Intervention
|
Changes in facial expressivity (frequency, intensity and duration of Duchenne smiles) will be assessed during an emotional interview, using objective facial coding.
|
4 weeks of Intervention
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
25 mei 2026
Primaire voltooiing (Geschat)
20 april 2028
Studie voltooiing (Geschat)
30 maart 2029
Studieregistratiedata
Eerst ingediend
25 mei 2026
Eerst ingediend dat voldeed aan de QC-criteria
2 juni 2026
Eerst geplaatst (Werkelijk)
5 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
8 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
4 juni 2026
Laatst geverifieerd
1 maart 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 24-155
- WI4 179978 (Ander subsidie-/financieringsnummer: Canadian Institutes of Health Research (CIHR))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .